Randomized clinical trials have shown that front-line treatment with first-, second-, and third-generation EGFR-tyrosine kinase inhibitors (TKIs) greatly improved the survival outcomes of advanced EGFR-mutated NSCLC patients [5]. Here, EGFR is linked to non-small cell lung carcinoma.